Geographic Area – Page 4

Lundbeck Offloads Assets to Three Partners as It Exits 27 Markets, Leaving 602 Jobless

2 months ago talkbio0Tagged asset, Exit, Lundbeck, Market, neuro-rare diseases, neuro-specialty diseases, NewBridge Pharmaceuticals, offloading, partnerships, restructuring, Swixx Group, Zuellig Pharma

Lundbeck; market exit; asset offloading; partnerships; job cuts; Swixx Group; Zuellig Pharma; NewBridge Pharmaceuticals; restructuring; neuro-rare diseases; neuro-specialty diseases

Regeneron and Sandoz Settle Eylea Biosimilar Patent Dispute

2 months ago talkbio0Tagged Approved, Biosimilars, Enzeevu, Eylea, launch, Ophthalmology specialty, Patent Settlement, Regeneron, sandoz, United States, United States Food and Drug Administration

Regeneron; Sandoz; Eylea; Enzeevu; biosimilar; aflibercept; patent settlement; FDA approval; U.S. launch; ophthalmology

Junshi Biosciences Announces Phase 3 Win for IL-17A Drug JS005 in Psoriasis, Prepares China NDA Submission

2 months ago talkbio0Tagged Biosciences, China, clinical endpoints, Drug Approval, IL-17A monoclonal antibody, JS005, Junshi, Psoriasis

Junshi Biosciences; JS005; IL-17A monoclonal antibody; psoriasis; phase 3 trial; clinical endpoints; China drug approval

BioNTech and DualityBio Achieve Phase 3 Success with ADC Therapy for HER2-Positive Breast Cancer, Advancing Oncology Pipeline

2 months ago talkbio0Tagged Antibody-Drug Conjugates, BioNTech, DualityBio, HER2-positive carcinoma of breast, Market, Oncology Pipeline, pamirtecan, Phase 3 trial, Progression-Free Survival, trastuzumab

BioNTech; DualityBio; antibody-drug conjugate (ADC); HER2-positive breast cancer; trastuzumab pamirtecan; BNT323/DB-1303; phase 3 trial; progression-free survival; oncology pipeline; ADC market

Japan Wins Exemption for Generics in US-Japan Trade Deal

2 months ago talkbio0Tagged generic pharmaceuticals, Japan, semiconductor supply chains, tariff exemption, TNFRSF19 gene, Transplant Registry Unified Management Program, U.S.

Japan; US Trade Deal; generic pharmaceuticals; tariff exemption; semiconductor supply chains; Trump administration

Sanofi Phase 3 Eczema Win Falls Short of Analyst Expectations

2 months ago talkbio0Tagged Amlitelimab, Dermatitis, Atopic, Dupixent, EASI-75, Eczema, Expectations, Market, Reaction, sanofi

Sanofi; amlitelimab; phase 3 trial; eczema; atopic dermatitis; analyst expectations; Dupixent; EASI-75; market reaction

Endpoints News to Announce 2025 ‘Endpoints 11’ Biotechs to Watch Live in Boston

2 months ago talkbio0Tagged Biopharma, biotech startups, City of Boston, Endpoints, Industry, innovation, live event, trends qualifier

Endpoints 11; biotech startups; biopharma; Boston; live event; industry trends; biotech innovation

AstraZeneca Ends Manufacturing License at Indian Plant and Exits Site as Part of Global Strategy

2 months ago talkbio0Tagged AstraZeneca, Bangalore plant, Contract agreement, Drug Industry, global strategy, India, Manufacturing, manufacturing license, Site of exit

AstraZeneca; India; manufacturing license; site exit; Bangalore plant; contract manufacturing; global strategy; pharmaceutical industry

Gilead Unveils New Manufacturing Site in California as Part of $32B U.S. Investment Plan

2 months ago talkbio0Tagged Billion, Biological Factors, California, economic impact, expansion, Foster City, Gilead Sciences, Investments, Manufacturing, Manufacturing Facilities, R&D, Surgical construction, United States

Gilead Sciences; Foster City; California; manufacturing facility; biopharmaceuticals; $32 billion investment; economic impact; expansion; R&D; job creation; U.S. manufacturing

Recent News on Scaling Up Cell & Gene Therapy Supply Chains (2025)

2 months ago talkbio0Tagged Automation, Cells, digital solutions, gene therapy, Growth, Logistics, Market, patient-specific therapies, risk mitigation, scalability, supply chain, white glove delivery

cell and gene therapy; supply chain; scalability; logistics; digital solutions; risk mitigation; white glove delivery; patient-specific therapies; automation; market growth